|
|
Am J Pathol. 1998 May; 152(5): 1187–1197. | PMCID: PMC1858591 |
Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma. H. Nagano, P. Libby, M. K. Taylor, S. Hasegawa, J. L. Stinn, G. Becker, N. L. Tilney, and R. N. Mitchell Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. Abstract This study evaluated the contribution of acute parenchymal rejection and interferon (IFN)-gamma to the development of graft arterial disease (GAD) in totally allogeneic murine cardiac transplants. BALB/c (H-2d) hearts were transplanted into wild-type C57BL/6 (B6, H-2b) or B6 IFN-gamma-deficient (GKO) recipient mice. Assessing the role of acute parenchymal rejection in the GAD process involved two different immunosuppression protocols using anti-CD4 and -CD8 monoclonal antibodies (MAbs): virtually complete long-term immunosuppression (denoted as complete immunosuppression) was achieved by administering both MAbs 6, 3, and 1 day before transplantation and weekly thereafter; in contradistinction, a single, early, transient episode of rejection (transient rejection) was attained by administering MAbs beginning 4 days after transplant and then at weekly intervals. The extent and duration of T cell depletion under these two regimens were evaluated using flow cytometric analysis of peripheral blood lymphocytes. After a single injection of MAbs, peripheral blood CD4+ and CD8+ T cell depletion was approximately 98% at 1 week and approximately 88% at 2 weeks. After three injections (analogous to days 6, 3, and 1 before transplant), peripheral blood CD4+ and CD8+ T cell depletion was >98% at 2 weeks and approximately 87% at 4 weeks. Functioning cardiac allografts were removed at 8 and 12 weeks after transplant and analyzed by hematoxylin and eosin, elastic tissue, and immunohistochemical stains, and the severity of parenchymal rejection versus GAD was scored. With complete immunosuppression (antibody before and after transplant), BALB/c allografts showed little parenchymal rejection or GAD, suggesting that persistent depletion of T cells blocked subsequent development of GAD. However, even a single transient acute rejection episode allowed the subsequent development of GAD accompanied by augmented major histocompatibility complex (MHC) class II, VCAM-1, and ICAM-1 expression at 12 weeks; these allografts showed no residual CD4+ or CD8+ T cells. In comparison, allografts undergoing transient rejection in GKO recipients did not develop GAD, despite persistent macrophage and natural killer cell (NK) infiltrates comparable to those seen in wild-type recipients. Moreover, the arterioles of hearts transplanted into GKO recipients showed no or minimal increases in MHC class II, ICAM-1, and VCAM-1 relative to baseline expression. In conclusion, a single episode of allogeneic injury mediated by T cells suffices to evoke subsequent graft arteriosclerosis, even in the absence of additional T-cell-mediated injury, and the process appears to depend on IFN-gamma. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (3.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. Images in this article Click on the image to see a larger version. These references are in PubMed. This may not be the complete list of references from this article. - Räisänen-Sokolowski A, Glysing-Jensen T, Koglin J, Russell ME. Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-gamma knockout recipients. Am J Pathol. 1998 Feb;152(2):359–365. [PubMed]
- Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Griffith BP, Hardesty RL, Trento A, Bahnson HT. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987 Oct;76(4):827–834. [PubMed]
- Paul LC, Fellström B. Chronic vascular rejection of the heart and the kidney--have rational treatment options emerged? Transplantation. 1992 Jun;53(6):1169–1179. [PubMed]
- Hosenpud JD, Shipley GD, Wagner CR. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant. 1992 Jan–Feb;11(1 Pt 1):9–23. [PubMed]
- Russell ME, Fujita M, Masek MA, Rowan RA, Billingham ME. Cardiac graft vascular disease. Nonselective involvement of large and small vessels. Transplantation. 1993 Dec;56(6):1599–1601. [PubMed]
- Libby P, Salomon RN, Payne DD, Schoen FJ, Pober JS. Functions of vascular wall cells related to development of transplantation-associated coronary arteriosclerosis. Transplant Proc. 1989 Aug;21(4):3677–3684. [PubMed]
- Hauptman PJ, Davis SF, Miller L, Yeung AC. The role of nonimmune risk factors in the development and progression of graft arteriosclerosis: preliminary insights from a multicenter intravascular ultrasound study. Multicenter Intravascular Ultrasound Transplant Study Group. J Heart Lung Transplant. 1995 Nov–Dec;14(6 Pt 2):S238–S242. [PubMed]
- Salomon RN, Hughes CC, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol. 1991 Apr;138(4):791–798. [PubMed]
- Dumont FJ, Dijkmans R, Palfree RG, Boltz RD, Coker L. Selective up-regulation by interferon-gamma of surface molecules of the Ly-6 complex in resting T cells: the Ly-6A/E and TAP antigens are preferentially enhanced. Eur J Immunol. 1987 Aug;17(8):1183–1191. [PubMed]
- Barr CL, Saunders GF. Interferon-gamma-inducible regulation of the human invariant chain gene. J Biol Chem. 1991 Feb 25;266(6):3475–3481. [PubMed]
- Drew PD, Lonergan M, Goldstein ME, Lampson LA, Ozato K, McFarlin DE. Regulation of MHC class I and beta 2-microglobulin gene expression in human neuronal cells. Factor binding to conserved cis-acting regulatory sequences correlates with expression of the genes. J Immunol. 1993 Apr 15;150(8 Pt 1):3300–3310. [PubMed]
- Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol. 1986 Jul 1;137(1):245–254. [PubMed]
- Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest. 1997 Aug 1;100(3):550–557. [PubMed]
- Liu G, Butany J. Morphology of graft arteriosclerosis in cardiac transplant recipients. Hum Pathol. 1992 Jul;23(7):768–773. [PubMed]
- Zerbe T, Uretsky B, Kormos R, Armitage J, Wolyn T, Griffith B, Hardesty R, Duquesnoy R. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant. 1992 May–Jun;11(3 Pt 2):S104–S110. [PubMed]
- Nakagawa T, Sukhova GK, Rabkin E, Winters GL, Schoen FJ, Libby P. Acute rejection accelerates graft coronary disease in transplanted rabbit hearts. Circulation. 1995 Aug 15;92(4):987–993. [PubMed]
- Hauptman PJ, Nakagawa T, Tanaka H, Libby P. Acute rejection: culprit or coincidence in the pathogenesis of cardiac graft vascular disease? J Heart Lung Transplant. 1995 Nov–Dec;14(6 Pt 2):S173–S180. [PubMed]
- Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993 Mar 19;259(5102):1739–1742. [PubMed]
- Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation. 1973 Oct;16(4):343–350. [PubMed]
- Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol. 1981 Jun;75(6):816–821. [PubMed]
- Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL, Zerbe A. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant. 1990 Nov–Dec;9(6):587–593. [PubMed]
- Saleem S, Konieczny BT, Lowry RP, Baddoura FK, Lakkis FG. Acute rejection of vascularized heart allografts in the absence of IFNgamma. Transplantation. 1996 Dec 27;62(12):1908–1911. [PubMed]
- Geerling RA, de Bruin RW, Scheringa M, Bonthuis F, Jeekel J, Ijzermans JN, Marquet RL. Suppression of acute rejection prevents graft arteriosclerosis after allogeneic aorta transplantation in the rat. Transplantation. 1994 Dec 15;58(11):1258–1263. [PubMed]
- Tullius SG, Hancock WW, Heemann U, Azuma H, Tilney NL. Reversibility of chronic renal allograft rejection. Critical effect of time after transplantation suggests both host immune dependent and independent phases of progressive injury. Transplantation. 1994 Jul 15;58(1):93–99. [PubMed]
- Izutani H, Miyagawa S, Shirakura R, Matsumiya G, Nakata S, Shimazaki Y, Matsuda H. Evidence that graft coronary arteriosclerosis begins in the early phase after transplantation and progresses without chronic immunoreaction. Histopathological analysis using a retransplantation model. Transplantation. 1995 Nov 27;60(10):1073–1079. [PubMed]
- Hullett DA, Geraghty JG, Stoltenberg RL, Sollinger HW. The impact of acute rejection on the development of intimal hyperplasia associated with chronic rejection. Transplantation. 1996 Dec 27;62(12):1842–1846. [PubMed]
- Russell ME, Hancock WW, Akalin E, Wallace AF, Glysing-Jensen T, Willett TA, Sayegh MH. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest. 1996 Feb 1;97(3):833–838. [PubMed]
- Shi C, Lee WS, He Q, Zhang D, Fletcher DL, Jr, Newell JB, Haber E. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4051–4056. [PubMed]
- Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol. 1988 Jun 15;140(12):4245–4252. [PubMed]
- Liu Y, Janeway CA., Jr Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med. 1990 Dec 1;172(6):1735–1739. [PubMed]
- Bucy RP, Hanto DW, Berens E, Schreiber RD. Lack of an obligate role for IFN-gamma in the primary in vitro mixed lymphocyte response. J Immunol. 1988 Feb 15;140(4):1148–1152. [PubMed]
- Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983 Sep 1;158(3):670–689. [PubMed]
- Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749–795. [PubMed]
- Skoskiewicz MJ, Colvin RB, Schneeberger EE, Russell PS. Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. J Exp Med. 1985 Nov 1;162(5):1645–1664. [PubMed]
- Collins T, Lapierre LA, Fiers W, Strominger JL, Pober JS. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci U S A. 1986 Jan;83(2):446–450. [PubMed]
- Thornhill MH, Wellicome SM, Mahiouz DL, Lanchbury JS, Kyan-Aung U, Haskard DO. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol. 1991 Jan 15;146(2):592–598. [PubMed]
- Thornhill MH, Haskard DO. IL-4 regulates endothelial cell activation by IL-1, tumor necrosis factor, or IFN-gamma. J Immunol. 1990 Aug 1;145(3):865–872. [PubMed]
- Thornhill MH, Kyan-Aung U, Haskard DO. IL-4 increases human endothelial cell adhesiveness for T cells but not for neutrophils. J Immunol. 1990 Apr 15;144(8):3060–3065. [PubMed]
- Pober JS, Gimbrone MA, Jr, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol. 1986 Sep 15;137(6):1893–1896. [PubMed]
- Tanaka H, Sukhova GK, Swanson SJ, Cybulsky MI, Schoen FJ, Libby P. Endothelial and smooth muscle cells express leukocyte adhesion molecules heterogeneously during acute rejection of rabbit cardiac allografts. Am J Pathol. 1994 May;144(5):938–951. [PubMed]
- Ardehali A, Laks H, Drinkwater DC, Ziv E, Drake TA. Vascular cell adhesion molecule-1 is induced on vascular endothelia and medial smooth muscle cells in experimental cardiac allograft vasculopathy. Circulation. 1995 Aug 1;92(3):450–456. [PubMed]
- Tanaka H, Sukhova GK, Libby P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler Thromb. 1994 May;14(5):734–745. [PubMed]
- Pelletier RP, Ohye RG, Vanbuskirk A, Sedmak DD, Kincade P, Ferguson RM, Orosz CG. Importance of endothelial VCAM-1 for inflammatory leukocytic infiltration in vivo. J Immunol. 1992 Oct 1;149(7):2473–2481. [PubMed]
- Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 1992 Feb 28;255(5048):1125–1127. [PubMed]
- Russell PS, Chase CM, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. IV Effects of treatment with monoclonal antibodies to intercellular adhesion molecule-1 and leukocyte function-associated antigen-1. Transplantation. 1995 Oct 15;60(7):724–729. [PubMed]
- Orosz CG, Ohye RG, Pelletier RP, Van Buskirk AM, Huang E, Morgan C, Kincade PW, Ferguson RM. Treatment with anti-vascular cell adhesion molecule 1 monoclonal antibody induces long-term murine cardiac allograft acceptance. Transplantation. 1993 Aug;56(2):453–460. [PubMed]
- Sadahiro M, McDonald TO, Allen MD. Reduction in cellular and vascular rejection by blocking leukocyte adhesion molecule receptors. Am J Pathol. 1993 Mar;142(3):675–683. [PubMed]
|